CSPC

CSPC Pharmaceutical Group Limited ("CSPC") (Stock Code: 1093.HK) is one of the well-known pharmaceutical listed companies in Hong Kong. The company was listed on the Main Board of the Hong Kong Stock Exchange in 1994 and became a constituent stock of the Hang Seng Index in 2018, being the first pharmaceutical stock in the history of the Hang Seng Index compilation. It is also a constituent stock of the Hang Seng Composite Index, Hang Seng Healthcare Index, Hang Seng China Mainland Healthcare Index, Hang Seng Stock Connect Index, Hang Seng China (Hong Kong Listed) 100 Index, and Hang Seng China Enterprises Index. CSPC mainly has two business segments: finished drugs and active pharmaceutical ingredients (API), with innovative drugs as the core development strategy of the company. CSPC currently has a strong product portfolio in therapeutic areas such as nervous system diseases, anti-tumor, anti-infective, and cardiovascular diseases, among which "NBP", "Duomeisu", "Jinyouli", "Keaili", and "Xuan Ning" are popular innovative products in China. API products mainly include vitamin C, antibiotics, and caffeine series. CSPC's main production base is located in Shijiazhuang City, Hebei Province, China.